abstract |
The present invention relates to the field of medicine, in particular to an antitumor pharmaceutical composition comprising chidamide and use thereof. The present invention provides an antitumor pharmaceutical composition, which comprises chidamide and an inhibitor of celular-mesenchymal epithelial transition factor (c-met), or chidamide and an inhibitor of anaplastic lymphoma kinase (ALK), or chidamide and a repressor of silencing 1 (ROS1). |